Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
"Solid third quarter with continued progress in our development pipeline, double-digit quarterly sales growth and strong results development"
Summary third quarter 2021
July - September- Total revenue amounted to SEK 154 (100) million, an increase of 54% (54% at CER[1]), whereof product sales were SEK 152 (94) million, an increase of 61% (62% at CER)
- Quarterly sales growth was 11% (12% at CER) compared to previous quarter
- Operating result was SEK -6 (-23) million, an increase of 73%
- Cash position at the end of the quarter was SEK 426 (476) million
- Buvidal® was launched in France and Slovenia
- FDA granted CAM2029 orphan drug designation in the US for the treatment of polycystic liver disease
- Positive clinical results with Buvidal were published in Drug and Alcohol Dependence and in American Journal of Drug and Alcohol Abuse
- Total revenue amounted to SEK 418 (230) million, an increase of 81% (83% at CER), whereof product sales were SEK 413 (219) million, an increase of 89% (90% at CER)
- Operating profit was -92 (-124) MSEK, an increase of 25%
- Outlook for the full year 2021 is downgraded, see report page 15[1,2]
1) At constant exchange rates in January 2021.
2) Excluding US$35 million milestone payment on approval of Brixadi™ in the US.
- Total Revenue MSEK 154 (100)
- OPEX MSEK 139 (113)
- Operating result MSEK -6 (-23)
- Result for the period MSEK -6 (-20)
- Results per share, before and after dilution, of SEK -0.11 (-0.38)
- Cash position MSEK 426 (476)
Fredrik Tiberg, President and CEO:
"Progress continued during the third quarter with the launch of a new Phase 3 study, granting of orphan drug designation for CAM2029 in the US, double-digit sales growth and improved results. COVID-19 has continued to put pressure on us, however, we see potential for accelerated growth as access to health care providers and patients improves and new markets are added. In December, we also await an important approval decision for Brixadi™ in the US."
Audiocast
Financial analysts and media are invited to attend a telephone conference and presentation of the results today at 2 pm (CET). The conference call can also be followed by a link on camurus.com or via external link:https://financialhearings.com/event/13367
For more information:
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com
About Camurus
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal[®] drug delivery technologies and its extensive R&D expertise. Camurus' clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.
This information is information that Camurus AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the chief executive officer, 07.00 AM (CET) on 4 November, 2021.